RecruitingNot ApplicableNCT07036328

Transcranial Magnetic Stimulation to Slow Down Cognitive Decline in Alzheimer's Disease

Transcranial Magnetic Stimulation (TMS) to Slow Down Cognitive Decline in Alzheimer's Disease (AD): TMSLA - a Monocentric Randomized Controlled Trial.

Sponsor

Willem de Haan

Enrollment

62 participants

Start Date

Apr 7, 2025

Study Type

INTERVENTIONAL

Conditions

Alzheimer Disease Alzheimer Disease, Early Onset

Summary

New amyloid-targeting drugs for Alzheimer's disease (AD) offer minimal or unclear efficacy and often cause adverse events, highlighting the need for new therapies. In recent years, repetitive transcranial magnetic stimulation (rTMS) has shown increasing success. A recent randomized, double-blind, sham-controlled, phase 2 demonstrated promising results from a 24-week rTMS treatment protocol targeting the precuneus. This brain region is considered a main hub of the human brain connectome and a prominent area of AD pathology. The results showed stable cognitive performance and increased brain activity in the treatment group, whereas the sham group worsened. A replication study is planned to further investigate the working mechanism of precuneus-rTMS in AD and to improve understanding of its therapeutic potential.

Eligibility

Min Age: 50 YearsMax Age: 85 Years

Plain Language Summary

Simplified for easier understanding

This study investigates whether transcranial magnetic stimulation (TMS) — a non-invasive brain stimulation technique using magnetic pulses — can slow memory and thinking decline in people with early Alzheimer's disease. **You may be eligible if...** - You are between 50 and 85 years old - You have a confirmed Alzheimer's diagnosis supported by brain scans or spinal fluid tests - You have mild cognitive impairment (MMSE score between 18 and 26) - You have a caregiver who can accompany you **You may NOT be eligible if...** - You have metal implants in your head (like a pacemaker or cochlear implant) - You have a history of seizures or epilepsy - Your cognitive impairment is severe Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICErepetitive transcranial magnetic stimulation

20 Hz repetitive transcranial magnetic stimulation targeted at the precuneus

DEVICEsham repetitive transcranial magnetic stimulation

20 Hz sham repetitive transcranial magnetic stimulation targeted at the precuneus

Locations(1)

Amsterdam UMC

Amsterdam, Netherlands

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07036328

Related Trials

Study of LHP588 in Subjects With P. Gingivalis-Positive Alzheimer's Disease

NCT0684732135 locations

A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-2)

NCT07011745140 locations

A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)

NCT07011732157 locations

A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)

NCT06585787288 locations

Phase II Trial to Evaluate Safety and Efficacy of GM-CSF/Sargramostim in Alzheimer's Disease

NCT049027031 location